Bite Back with Abbey Sharp

The PINK PILL for Women's Sexual Desire - Why it Took 10x Longer for Women's Addyi vs Men's Viagara with Cindy Eckert & Julie Bristow

Episode Summary

In today’s episode of Bite Back with Abbey Sharp, we explore the politics, science, and cultural debate surrounding women’s sexual desire and the development of the first FDA-approved medication for low libido. Joined by Julie Bristow, executive producer of the documentary The Pink Pill: Sex, Drugs, and Who Has Control, and Cindy Eckert, founder of Sprout Pharmaceuticals, we unpack the long road to bringing Addyi to market and what the fight for a “female Viagra” reveals about gender bias in medicine, sexual autonomy, and whose health needs are prioritized.

Episode Notes

Here’s a run down of what we discussed in today’s episode:

What Is Addyi? The First FDA-Approved Treatment for Low Female Desire
Addyi vs Viagra: Why the “Pink Pill” Took 17 Years to Approve
Cultural Bias in Medicine: Why Women’s Sexual Health Was Dismissed
Why This Story Matters Now: The Documentary The Pink Pill
Feminism, Pharma & Politics: Navigating a Controversial Topic
Understanding HSDD: Biology vs Context in Low Sexual Desire
Can a Medication Empower Women’s Sexual Autonomy?
Who Really Has Control? Power, Partners & the Medical System
Addyi, Ozempic & the Shift From Moral Judgment to Biology
Sexual Autonomy, Systemic Change & What True Choice Looks Like

Check in with today’s amazing guest: Julie Bristow & Cindy Eckert

The Pink Pill

Disclaimer: The content in this episode is for educational and entertainment purposes only and is never a substitute for medical advice. If you’re struggling with with your mental or physical health, please work one on one with a health care provider.

If you have heard yourself in our discussion today, and are looking for support, contact the free NEDIC helpline at 1-866-NEDIC-20 or go to eatingdisorderhope.com.